<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01159574</url>
  </required_header>
  <id_info>
    <org_study_id>1004011012</org_study_id>
    <secondary_id>PO-MM-PI-0023</secondary_id>
    <nct_id>NCT01159574</nct_id>
  </id_info>
  <brief_title>Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma</brief_title>
  <official_title>A Phase II Study of Dexamethasone (DECADRON®), Clarithromycin (BIAXIN®), and Pomalidomide (CC-4047®) for Subjects With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to investigate the combination of the combination of dexamethasone
      (Decadron®), Clarithromycin (Biaxin®), and pomalidomide (CC-4047®) [ClaPd] in multiple
      myeloma patients who have relapsed or refractory disease who have failed prior treatment with
      lenalidomide when used alone or in combination with corticosteroids. Primary endpoint will be
      response rate to treatment. Secondary endpoints will include toxicity of the combination,
      time to maximum response, and time to disease progression
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase II study is a treatment program for patients with relapsed or refractory multiple
      myeloma who have had prior treatment with lenalidomide. Up to 54 patients will be enrolled.
      Patients who sign informed consent form and fulfill all eligibility criteria will be
      enrolled.

      ClaPd therapy:

      Dexamethasone (40mg ) on days 1, 8, 15, 22 of a 28-day cycle. Clarithromycin given orally at
      a dose of 500 mg twice a day on days 1-28 of a 28 day cycle.

      Pomalidomide will be given 4mg daily for days 1-21 of each 28 day cycle.

      Serial clinic visits and laboratory measurements will be performed to monitor for treatment
      response. Those patients who demonstrate progression of disease at any point during ClaPd
      therapy will be taken off study.

      At the end of every cycle (which may coincide with day 1 of the new cycle), response and
      toxicity will be evaluated. During cycle 1, patients will have labwork done weekly (CBC with
      differential and blood electrolytes). All patients will remain on study until disease
      progression or side effects become excessive. Patients who achieve a stable plateau may be
      taken off study if eligible to proceed to high dose chemotherapy and autologous stem cell
      transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2010</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>from baseline to cycle with maximum response, which was achieved on average after 2 cycles</time_frame>
    <description>Best response rate was recorded for all patients, using the IMWG criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Response, Expressed as Number of Cycles of Treatment to Maximum Response</measure>
    <time_frame>From baseline to cycle of maximum response, which occurred on average after 2 cycles; 1 cycle = 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression (Progression Free Survival)</measure>
    <time_frame>From start of treatment, to date of disease progression</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>all patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ClaPd therapy:
Dexamethasone (40mg ) will be given on days 1, 8, 15, 22 of a 28-day cycle. Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle.
Pomalidomide will be given 4mg daily for days 1-21 of each 28 day cycle. Dosing will be in the morning at approximately the same time each day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>40mg will be given on days 1, 8, 15, 22 of a 28-day cycle</description>
    <arm_group_label>all patients</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clarithromycin</intervention_name>
    <description>orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle</description>
    <arm_group_label>all patients</arm_group_label>
    <other_name>Biaxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>orally 4mg daily for days 1-21 of each 28 day cycle</description>
    <arm_group_label>all patients</arm_group_label>
    <other_name>CC-4047</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must voluntarily sign and understand written informed consent.

          -  Age &gt; 18 years at the time of signing the consent form.

          -  Histologically confirmed MM

          -  Relapsed or refractory myeloma, progression of disease either after prior therapy or
             lack of response to currently used therapy.

          -  Relapsed or progressive disease after at least 3 prior therapeutic treatments or
             regimens for multiple myeloma.

          -  Must have been previously treated with lenalidomide and has been determined to be
             refractory, resistant, or relapsed.

          -  Measurable disease as defined by &gt; 0.5 g/dL serum monoclonal protein, &gt;0.1 g/dL serum
             free light chains, &gt;0.2 g/24 hrs urinary M-protein excretion, and/or measurable
             plasmacytoma(s).

          -  Karnofsky performance status ≥70% (&gt;60% if due to bony involvement of myeloma

          -  Females of childbearing potential (FCBP)† must have a negative serum or urine
             pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to
             and again within 24 hours of prescribing lenalidomide and thalidomide (prescriptions
             must be filled within 7 days) and must either commit to continued abstinence from
             heterosexual intercourse or begin TWO acceptable methods of birth control, one highly
             effective method and one additional effective method AT THE SAME TIME, at least 4
             weeks before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy
             testing. Men must agree to use a latex condom during sexual contact with females of
             child bearing potential even if they have had a successful vasectomy. See Appendix V:
             Pomalidomide Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable
             Birth Control Methods. †A female of childbearing potential is a sexually mature woman
             who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been
             naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at
             any time in the preceding 24 consecutive months).

          -  Able to take aspirin daily as prophylactic anticoagulation (patients intolerant to ASA
             may use warfarin or low molecular weight heparin). †

          -  1ife expectancy ≥ 3 months

          -  Subjects must meet the following laboratory parameters:

        Absolute neutrophil count (ANC) ≥750 cells/mm3 (1.0 x 109/L) Platelets count ≥ 50,000/mm3
        (75 x 109/L) Serum SGOT/AST ≤ 2.0 x upper limits of normal Serum SGPT/ALT &lt;3.0 x upper
        limits of normal (ULN) Serum creatinine ≤ 2.5 x upper limits of normal Serum total
        bilirubin ≤ 1.5 x upper limits of normal

        Exclusion Criteria:

          -  Patients with non-secretory MM (no measurable monoclonal protein, free light chains,
             and/or M-spike in blood or urine).

          -  Prior history of other malignancies (except for basal cell or squamous cell carcinoma
             of the skin or carcinoma in situ of the cervix or breast) unless disease free for ≥ 5
             years.

          -  Myocardial infarction within 6 months prior to enrollment, or NYHA(New York Hospital
             Association) Class III or IV heart failure, uncontrolled angina, severe uncontrolled
             ventricular arrhythmias, electrocardiographic evidence of acute ischemia or active
             conduction system abnormalities.

          -  Known HIV infection

          -  Known hepatitis B or hepatitis C infection.

          -  Active viral or bacterial infections or any coexisting medical problem that would
             significantly increase the risks of this treatment program.

          -  Any coexisting medical problem or laboratory evaluation that, in the treating
             physician's or principal investigator's opinion, makes the patient unsuitable to
             participate in this clinical trial.

          -  Known hypersensitivity to thalidomide or lenalidomide.

          -  History of thromboembolic event within the past 6 months prior to enrollment.

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form.

          -  Pregnant or breast feeding females.

          -  Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study.

          -  Use of any other experimental drug or therapy within 14 days of baseline.

          -  Known hypersensitivity to thalidomide or lenalidomide.

          -  The development of erythema nodorum if characterized by a desquamating rash while
             taking thalidomide, CC-4047 or similar drugs.

          -  Any prior use of CC-4047.

          -  Concurrent use of other anti-cancer agents or treatments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruben Niesvizky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.med.cornell.edu/cancercare/trials</url>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2010</study_first_submitted>
  <study_first_submitted_qc>July 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2010</study_first_posted>
  <results_first_submitted>February 28, 2017</results_first_submitted>
  <results_first_submitted_qc>February 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2017</results_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Patients</title>
          <description>ClaPd therapy:
Dexamethasone (40mg ) will be given on days 1, 8, 15, 22 of a 28-day cycle. Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle.
Pomalidomide will be given 4mg daily for days 1-21 of each 28 day cycle. Dosing will be in the morning at approximately the same time each day.
dexamethasone: 40mg will be given on days 1, 8, 15, 22 of a 28-day cycle
clarithromycin: orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle
Pomalidomide: orally 4mg daily for days 1-21 of each 28 day cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>non-evaluable/not included in analysis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>still on treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow Up Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92">Completion defined as those that are no longer in long term follow up due to death.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>still being followed for overall surviva</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>121 subject signed consent; 1 subject was not considered to be evaluable and was not included in any analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>All Patients</title>
          <description>ClaPd therapy:
Dexamethasone (40mg ) will be given on days 1, 8, 15, 22 of a 28-day cycle. Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle.
Pomalidomide will be given 4mg daily for days 1-21 of each 28 day cycle. Dosing will be in the morning at approximately the same time each day.
dexamethasone: 40mg will be given on days 1, 8, 15, 22 of a 28-day cycle
clarithromycin: orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle
Pomalidomide: orally 4mg daily for days 1-21 of each 28 day cycle</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="42" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin</title>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.4" lower_limit="6.4" upper_limit="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Range of Prior Therapies</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" lower_limit="3" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beta-2 microglobulin at baseline (in mg/L)</title>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" lower_limit="1.2" upper_limit="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>lactage dehydrogenase at baseline (U/L)</title>
          <units>u/l</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.5" lower_limit="79" upper_limit="1353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate</title>
        <description>Best response rate was recorded for all patients, using the IMWG criteria.</description>
        <time_frame>from baseline to cycle with maximum response, which was achieved on average after 2 cycles</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>ClaPd therapy:
Dexamethasone (40mg ) will be given on days 1, 8, 15, 22 of a 28-day cycle. Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle.
Pomalidomide will be given 4mg daily for days 1-21 of each 28 day cycle. Dosing will be in the morning at approximately the same time each day.
dexamethasone: 40mg will be given on days 1, 8, 15, 22 of a 28-day cycle
clarithromycin: orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle
Pomalidomide: orally 4mg daily for days 1-21 of each 28 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Best response rate was recorded for all patients, using the IMWG criteria.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>stringent Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very Good Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Minimal Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>stable disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>progression of disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Response, Expressed as Number of Cycles of Treatment to Maximum Response</title>
        <time_frame>From baseline to cycle of maximum response, which occurred on average after 2 cycles; 1 cycle = 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>ClaPd therapy:
Dexamethasone (40mg ) will be given on days 1, 8, 15, 22 of a 28-day cycle. Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle.
Pomalidomide will be given 4mg daily for days 1-21 of each 28 day cycle. Dosing will be in the morning at approximately the same time each day.
dexamethasone: 40mg will be given on days 1, 8, 15, 22 of a 28-day cycle
clarithromycin: orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle
Pomalidomide: orally 4mg daily for days 1-21 of each 28 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Response, Expressed as Number of Cycles of Treatment to Maximum Response</title>
          <units>cycles</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" lower_limit="1" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease Progression (Progression Free Survival)</title>
        <time_frame>From start of treatment, to date of disease progression</time_frame>
        <population>18 patients were removed from study for reasons other then disease progression; 2 patients are still receiving treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>ClaPd therapy:
Dexamethasone (40mg ) will be given on days 1, 8, 15, 22 of a 28-day cycle. Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle.
Pomalidomide will be given 4mg daily for days 1-21 of each 28 day cycle. Dosing will be in the morning at approximately the same time each day.
dexamethasone: 40mg will be given on days 1, 8, 15, 22 of a 28-day cycle
clarithromycin: orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle
Pomalidomide: orally 4mg daily for days 1-21 of each 28 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression (Progression Free Survival)</title>
          <population>18 patients were removed from study for reasons other then disease progression; 2 patients are still receiving treatment.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="272" lower_limit="21" upper_limit="1430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded from baseline until removal from study. Serious adverse events were recorded from baseline until 30 days after the last dose of study drug.</time_frame>
      <desc>Adverse events were recorded using the CTCAE version 4.0. The adverse events listed includes serious adverse events. Serious adverse events were recorded from baseline unti</desc>
      <group_list>
        <group group_id="E1">
          <title>All Patients</title>
          <description>ClaPd therapy:
Dexamethasone (40mg ) will be given on days 1, 8, 15, 22 of a 28-day cycle. Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle.
Pomalidomide will be given 4mg daily for days 1-21 of each 28 day cycle. Dosing will be in the morning at approximately the same time each day.
dexamethasone: 40mg will be given on days 1, 8, 15, 22 of a 28-day cycle
clarithromycin: orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle
Pomalidomide: orally 4mg daily for days 1-21 of each 28 day cycle</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>b</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>pancytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>bowel obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>diffuse small bowl ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>transient word finding difficulity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>weakness (including associated pain/tiredness)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>diverticullitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>lung infection</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>neutropenic fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>parainfluenza virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>renal insufficiency</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>rhinovirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>skin infection (including cellulitis)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>complications of MM (leading to death)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>intrcranial bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>pain (hip, rib)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>pain (rib)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>lower back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>muscle weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>suspected seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>altered mental status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>behavior changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>hallunication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>syncopal episode</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>chronic kidney insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>pulmonary emboli</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>thromboembolic event</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>blurry vision</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>cramping</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>bloating</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>abdominal pain/discomfort</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>flatulance</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fall</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>generalized weakness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Thrush</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>UTI</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>lung infection</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>URI</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>weight gain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>elevated AST</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>elevated ALT</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>elevated ALK</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>increased creatinine</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>bone pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>chest pain (muscular)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>pain in general</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>pain in legs</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>hip pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>rib pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>shoulder pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>muscle spasms/cramps</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>neuro mood</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>psychomotor agitation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>agitation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>anxiety/stress</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>dizziness / lightheaded</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>tremor</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>peripheral neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal failure/insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>CKD</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>hoarseness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>postnasal drip</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>cushingoid</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>rash maculo papular</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>facial flushing</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lower extremity DVT</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>bruising</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Hess</name_or_title>
      <organization>Weill Cornell Medical College</organization>
      <phone>6469629440</phone>
      <email>jmh2004@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

